These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 22366591)

  • 1. Bevacizumab rechallenge after first line maintenance bevacizumab.
    Konstantinopoulos PA; Berlin ST; Campos SM; Matulonis UA; Cannistra SA
    Gynecol Oncol; 2012 May; 125(2):510-1. PubMed ID: 22366591
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
    McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
    Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in ovarian cancer: unanswered questions.
    Muggia F
    Drugs; 2012 May; 72(7):931-6. PubMed ID: 22564133
    [No Abstract]   [Full Text] [Related]  

  • 4. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view.
    Tomao F; Tomao S; Panici PB
    J Clin Oncol; 2013 Jan; 31(1):166-7. PubMed ID: 23169499
    [No Abstract]   [Full Text] [Related]  

  • 6. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
    Dao MD; Alwan LM; Gray HJ; Tamimi HK; Goff BA; Liao JB
    Gynecol Oncol; 2013 Aug; 130(2):295-9. PubMed ID: 23632207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
    Kuwabara H; Baba H; Wakabayashi M; Nakamura H; Sanada T; Baba H; Nakajima K; Goseki N
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2250-2. PubMed ID: 22202345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma.
    Arora N; Tewari D; Cowan C; Saffari B; Monk BJ; Burger RA
    Int J Gynecol Cancer; 2008; 18(2):369-72. PubMed ID: 17624986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.
    Rocereto TF; Brady WE; Shahin MS; Hoffman JS; Small L; Rotmensch J; Mannel RS
    Gynecol Oncol; 2010 Mar; 116(3):332-4. PubMed ID: 19922989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and response to bevacizumab--letter.
    Cremolini C; Loupakis F; Bocci G; Falcone A
    Clin Cancer Res; 2014 Feb; 20(4):1056-7. PubMed ID: 24536076
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Administration-limiting factor of bevacizumab for patient with metastatic colorectal cancer].
    Kawazoe Y; Hatake K; Suenaga M; Mizunuma N
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():472-6. PubMed ID: 22214006
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers and response to bevacizumab--response.
    Collinson F; Hutchinson M; Craven RA; Cairns DA; Alexandre Z; Wind TC; Gahir N; Messenger MP; Jackson S; Thompson D; Adusei C; Ledermann J; Hall G; Jayson GC; Selby PJ; Banks RE
    Clin Cancer Res; 2014 Feb; 20(4):1058. PubMed ID: 24536077
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer.
    Stefanadis C; Synetos A; Tousoulis D; Tsiamis E; Michelongona A; Zagouri F; Bamias A; Dimopoulos MA; Kyvelou S; Kapelakis I; Toutouzas K
    Int J Cardiol; 2012 Feb; 154(3):341-4. PubMed ID: 22078988
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.